Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:FENCNASDAQ:IKNANASDAQ:PROKNASDAQ:VECT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCFennec Pharmaceuticals$9.07-1.8%$10.05$6.30▼$11.92$250.40M0.38115,039 shs182,107 shsIKNAIkena Oncology$1.29-4.4%$1.41$1.02▼$7.64$65.15M0.33234,047 shs154,016 shsPROKProKidney$2.71+7.1%$1.66$1.12▼$13.51$621.51M1.08686,654 shs530,676 shsVECTVectivBio$16.85$16.85$4.25▼$16.98N/AN/AN/AN/AElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCFennec Pharmaceuticals-1.84%-6.49%-17.55%-12.96%+14.09%IKNAIkena Oncology-4.44%+4.03%-10.42%0.00%-73.67%PROKProKidney+7.11%-4.58%+88.19%+71.52%-74.07%VECTVectivBio0.00%0.00%0.00%0.00%+47.16%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFENCFennec Pharmaceuticals2.4636 of 5 stars3.50.00.00.02.42.51.9IKNAIkena Oncology1.9292 of 5 stars3.53.00.00.00.01.71.3PROKProKidney1.5979 of 5 stars3.21.00.00.02.93.30.0VECTVectivBioN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFENCFennec Pharmaceuticals3.00Buy$17.3391.11% UpsideIKNAIkena Oncology3.00Buy$9.50636.43% UpsidePROKProKidney2.33Hold$9.50250.55% UpsideVECTVectivBio2.00HoldN/AN/ACurrent Analyst RatingsLatest FENC, VECT, IKNA, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/19/2024IKNAIkena OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.003/18/2024FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.003/12/2024IKNAIkena OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.003/7/2024PROKProKidneyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$3.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFENCFennec Pharmaceuticals$21.25M11.57N/AN/A($0.43) per share-21.09IKNAIkena Oncology$9.16M6.80N/AN/A$3.52 per share0.37PROKProKidneyN/AN/AN/AN/A($4.84) per shareN/AVECTVectivBio$27.34MN/AN/AN/A$6.27 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFENCFennec Pharmaceuticals-$16.05M-$0.61N/A12.96N/A-75.50%N/A-73.64%5/9/2024 (Estimated)IKNAIkena Oncology-$68.17M-$1.64N/AN/AN/AN/A-44.21%-37.27%5/20/2024 (Estimated)PROKProKidney-$35.47M-$0.57N/AN/AN/AN/AN/A-7.66%5/9/2024 (Estimated)VECTVectivBio-$93.74MN/A0.00∞N/AN/AN/AN/AN/ALatest FENC, VECT, IKNA, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023FENCFennec Pharmaceuticals$0.02-$0.10-$0.12-$0.10$9.47 million$9.74 million3/21/2024Q4 2023PROKProKidney-$0.19-$0.09+$0.10-$0.09N/AN/A3/12/2024Q4 2023IKNAIkena Oncology-$0.41-$0.41N/A-$0.41$2.39 million$0.66 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AIKNAIkena OncologyN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/AVECTVectivBioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFENCFennec PharmaceuticalsN/A3.563.27IKNAIkena OncologyN/A12.5812.58PROKProKidneyN/A14.9414.94VECTVectivBioN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipFENCFennec Pharmaceuticals55.51%IKNAIkena Oncology75.00%PROKProKidney51.59%VECTVectivBioN/AInsider OwnershipCompanyInsider OwnershipFENCFennec Pharmaceuticals11.25%IKNAIkena Oncology5.95%PROKProKidney44.99%VECTVectivBio9.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableFENCFennec PharmaceuticalsN/A27.10 million24.05 millionOptionableIKNAIkena Oncology4348.26 million45.39 millionNot OptionablePROKProKidney163229.34 million126.16 millionOptionableVECTVectivBioN/AN/AN/ANo DataFENC, VECT, IKNA, and PROK HeadlinesSourceHeadlineShort Bowel Syndrome Market by 2032: Forecast Report Estimates Significant Growthuk.finance.yahoo.com - April 5 at 12:23 PMRegency Capital Management Inc. DE Has $8.59 Million Position in VectivBio Holding AG (NASDAQ:VECT)marketbeat.com - April 3 at 10:15 PMFDA approves DMD treatment from Italfarmacocen.acs.org - March 31 at 2:32 PMPipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpointsmsn.com - March 18 at 5:04 PMIronwood Nabs Phase III Win, Still Sees Stock Nosedivebiospace.com - March 1 at 2:31 PMIronwood felled by mixed data in short bowel syndrome trialpharmaphorum.com - March 1 at 4:29 AMUPDATE 3-Ironwood's bowel disease drug meets main goal of late-stage studymsn.com - March 1 at 4:29 AMIronwood's bowel disease treatment meets main goal in late-stage trialreuters.com - February 29 at 12:16 PMWhy Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?benzinga.com - February 29 at 12:16 PMOnly two sleeps left until February 31!ft.com - February 29 at 7:16 AMShort Bowel Syndrome Market Size and Share is Anticipated to Surge During the Study Period (2020–2034) | DelveInsightfinance.yahoo.com - February 22 at 2:08 PMIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 16 at 1:12 PMIFLR Europe Awards 2024: shortlist revealediflr.com - February 8 at 8:11 AMIronwood seals the deal on VectivBio mergermsn.com - December 13 at 10:31 PMIronwood Announces the Completion of Squeeze-Out Merger With VectivBiofinance.yahoo.com - December 12 at 4:28 PMReverb Therapeutics Debuts Its Amplifier™ Platform for Redirecting Endogenous Cytokinestmcnet.com - November 15 at 10:15 AMIronwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Risesmsn.com - November 10 at 1:03 PMAkash Tewari’s Buy Rating on Ironwood Pharma: Linzess Floor Trading and Apraglutide’s Promising Futuremarkets.businessinsider.com - November 10 at 8:02 AMHold Rating for Ironwood Pharma Driven by Stable Linzess Revenue and Anticipated Apraglutide Data, Despite T Cell Data Delaymarkets.businessinsider.com - November 10 at 8:02 AMIronwood Pharmaceuticals Inc (IRWD) Reports Growth in LINZESS Sales and Maintains Full Year Guidancefinance.yahoo.com - November 9 at 10:44 AMConstipation Treatment Market is predicted to procure USD 10.1 Bn by 2032, Grow at a CAGR of 5.6%pharmiweb.com - October 31 at 7:35 AMIronwood Pharmaceuticals: The Right Play Nowmsn.com - October 27 at 5:16 PMIronwood Pharmaceuticals’ Apraglutide Shows Promising Results in STARS Nutrition and VectivBio Trials: An Emphasis on Jason Butler’s Buy Ratingmarkets.businessinsider.com - October 16 at 6:14 PMTransatlantic M&A bull run set for comebackjdsupra.com - September 15 at 4:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsFennec PharmaceuticalsNASDAQ:FENCFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Ikena OncologyNASDAQ:IKNAIkena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.ProKidneyNASDAQ:PROKProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.VectivBioNASDAQ:VECTVectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.